Company overview
TriLink BioTechnologies, part of Maravai LifeSciences, is a leading CDMO specializing in nucleic acid synthesis, including mRNA, oligonucleotides, plasmids, NTPs, and mRNA capping analogs like proprietary CleanCap® technology. They provide scalable manufacturing from research-grade (RUO) to full cGMP for therapeutic, vaccine, and diagnostic applications, with expertise in process development, scale-up, and technology transfer. Operating from a 118,000 sq. ft. facility in San Diego's Sorrento Valley, TriLink supports biopharma from early research to commercial production.
TriLink BioTechnologies is listed in the NovaPharmaNews Supplier Hub as a CDMO & Manufacturing partner serving United States & Americas. Core focus areas include mrna manufacturing, oligonucleotide synthesis, cgmp cdmo, cleancap technology, nucleic acid cdmo.
Industry categories: CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with TriLink BioTechnologies include Cdmo, Synthesis — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.trilinkbiotech.com
- Categories
- CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- mrna manufacturing, oligonucleotide synthesis, cgmp cdmo, cleancap technology, nucleic acid cdmo
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What manufacturing capabilities does TriLink offer for mRNA and oligonucleotides?
- TriLink provides a full range of manufacturing from research-grade (RUO) to customizable intermediate-grade GMPLinkTM and full GMP-grade, including cGMP mRNA, oligonucleotide, and plasmid production with scale-up and technology transfer expertise at their San Diego facility.
- What is TriLink's CleanCap® technology and its benefits?
- CleanCap® is a proprietary co-transcriptional mRNA capping reagent that simplifies manufacturing by eliminating enzymatic steps, delivering high capping efficiency, improved yields, and supporting over 350 clinical programs and 3 approved vaccines.
- Where are TriLink's facilities located and what do they support?
- TriLink operates a custom-built 118,000 sq. ft. facility in San Diego's Sorrento Valley with over 50,000 sq. ft. of manufacturing space, supporting process development, oligonucleotide synthesis, custom mRNA synthesis, cGMP manufacturing, analytical services, and in vivo gene editing.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
